{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:47:00Z","timestamp":1777603620006,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Significant disparities exist in axillary management between and within countries, particularly regarding patients undergoing neo-adjuvant chemotherapy (NAC) who present with nodal disease and subsequently become ycN0 after systemic treatment. The aim of this study was to evaluate the efficacy and safety of the single-tracer technique for clinically node-positive (cN\u2009+) breast cancer patients who achieve node-negativity (ycN0) after NAC and compare this approach with the dual-tracer technique. We included consecutive patients diagnosed with cT1-T2, cN1-N2 breast cancer who underwent NAC and achieved nodal disease regression (ycN0). The patients were divided into two groups: \u201cdual tracer\u201d technique for sentinel lymph node identification and \u201csingle tracer\u201d technique. In both groups, axillary lymph node dissection (ALND) was performed in patients with positive sentinel lymph nodes. Out of the 76 patients included, 42 underwent sentinel lymph node removal using the dual-tracer technique, while 34 underwent the single-tracer technique. In the single-tracer group, an average of two lymph nodes were removed per patient versus an average of three lymph nodes per patient in the dual-tracer group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001). No loco-regional recurrences have been reported in either group at a mean follow-up of 34\u00a0months. The single-tracer technique can be a reliable method for the axillary management in cN\u2009+\u2009breast cancer patients undergoing neo-adjuvant chemotherapy and achieving nodal disease regression (ycN0), in terms of loco-regional recurrences. This demonstrates that even if fewer sentinel lymph nodes are identified using the single tracer technique (and potentially the false negative rate of the procedure is higher), this does not impact on the rate of loco-regional recurrences. However, longer follow-up is required to confirm these findings.\n                  <\/jats:p>","DOI":"10.1007\/s13304-025-02441-5","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:58:40Z","timestamp":1761753520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Axillary management in the post-neoadjuvant setting: dual tracer vs. single tracer for sentinel lymph node biopsy"],"prefix":"10.1007","author":[{"given":"Alessia Luciana","family":"Margherita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizia","family":"Calenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pontillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Luigi Junior","family":"Castiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafalda","family":"Ingenito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunzio","family":"Velotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Musella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2441_CR1","doi-asserted-by":"crossref","unstructured":"Giuliano AE, Kirgan DM, Guenther JM, Morton DL (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391\u2013398, discussion 398\u2013401","DOI":"10.1097\/00000658-199409000-00015"},{"issue":"10","key":"2441_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"Armando E Giuliano","year":"2017","unstructured":"Giuliano Armando E, Ballman Karla V, McCall Linda, Beitsch Peter D, Brennan Meghan B, Kelemen Pond R, Ollila David W, Hansen Nora M, Whitworth Pat W, Blumencranz Peter W, Marilyn Leitch A, Saha Sukamal, Hunt Kelly K, Morrow Monica (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318(10):918\u2013926","journal-title":"JAMA"},{"key":"2441_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejso.2019.08.012","volume":"46","author":"JM Simons","year":"2020","unstructured":"Simons JM, Maaskant-Braat AJ, Luiten EJ, Leidenius MH, van Nijnatten TJ, Boelens PG et al (2020) Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy: re-sults of a survey amongst breast cancer specialists. Eur J Surg Oncol 46:53\u201358","journal-title":"Eur J Surg Oncol"},{"key":"2441_CR4","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-017-5958-4","volume":"24","author":"AS Caudle","year":"2017","unstructured":"Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK et al (2017) Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of American Society of Breast Surgeons Members. Ann Surg Oncol 24:2925\u20132934","journal-title":"Ann Surg Oncol"},{"key":"2441_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF et al (2019) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat 173:343\u2013352","journal-title":"Breast Cancer Res Treat"},{"key":"2441_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609\u2013618","journal-title":"Lancet Oncol"},{"key":"2441_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B et al (2013) Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455\u20131461","journal-title":"JAMA"},{"key":"2441_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/SLA.0000000000000551","volume":"261","author":"JC Boughey","year":"2015","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B et al (2015) Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 261:547\u201352","journal-title":"Ann Surg"},{"key":"2441_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","volume":"42","author":"V Galimberti","year":"2016","unstructured":"Galimberti V, Ribeiro Fontana SK, Maisonneuve P, Steccanella F, Vento AR, Intra M et al (2016) Sentinel node biopsy after neoadjuvant treatment in breast cancer: five year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 42:361\u2013368","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"2441_CR10","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3390\/cancers15061719","volume":"15","author":"C Tinterri","year":"2023","unstructured":"Tinterri C, Sagona A, Barbieri E, Di Maria GS, Caraceni G, Ambrogi G, Jacobs F, Biondi E, Scardina L, Gentile D (2023) Sentinel lymph node biopsy in breast cancer patients undergoing neo-adjuvant chemotherapy: clinical experience with node-negative and node-positive disease prior to systemic therapy. Cancers (Basel) 15(6):1719. https:\/\/doi.org\/10.3390\/cancers15061719","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2441_CR11","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.ejso.2018.05.035","volume":"44","author":"S Hartmann","year":"2018","unstructured":"Hartmann S, Reimer T, Gerber B, Stubert J, Stengel B, Stachs A (2018) Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. Eur J Surg Oncol 44(9):1307\u20131311. https:\/\/doi.org\/10.1016\/j.ejso.2018.05.035","journal-title":"Eur J Surg Oncol"},{"key":"2441_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.breast.2023.03.005","volume":"69","author":"Martin Heidinger","year":"2023","unstructured":"Heidinger Martin, Knauer Michael, Tausch Christoph, Weber Walter P (2023) Tailored axillary surgery \u2013 a novel concept for clinically node positive breast cancer. The Breast 69:281\u2013289","journal-title":"The Breast"},{"key":"2441_CR13","unstructured":"Diagnosis and Treatment of Patients with early and advanced Breast Cancer. Published by AGO Breast Committee (represented by: Wolfgang Janni) of the German Working Group Gynecological Oncology 2019"},{"key":"2441_CR14","unstructured":"German S3 Guideline on Breast Cancer. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018 AWMF Registernummer: 032\u2013045OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/ mammakarzinom\/ (accessed: Dec 11th 2019)"},{"key":"2441_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2015.63","volume":"12","author":"TA King","year":"2015","unstructured":"King TA, Morrow M (2015) Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol 12:335\u2013343","journal-title":"Nat Rev Clin Oncol"},{"key":"2441_CR16","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672\u20132685","journal-title":"J Clin Oncol"},{"issue":"1","key":"2441_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1245\/s10434-020-08593-5","volume":"28","author":"O Petruolo","year":"2020","unstructured":"Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV (2020) How often does Modern Neoadjuvant Chemotherapy (NAC) downstage patients to Breast-Conserving Surgery (BCS)? Annals Surg Oncol 28(1):287","journal-title":"Annals Surg Oncol"},{"key":"2441_CR18","doi-asserted-by":"crossref","unstructured":"Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, et al (2014) Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 260:608\u2013614, discussion 614\u20136","DOI":"10.1097\/SLA.0000000000000924"},{"key":"2441_CR19","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M (2020) Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol 27:4515\u20134522","journal-title":"Ann Surg Oncol"},{"key":"2441_CR20","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1200\/JCO.2007.15.3510","volume":"26","author":"JR Gralow","year":"2008","unstructured":"Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G et al (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814\u2013819","journal-title":"J Clin Oncol"},{"key":"2441_CR21","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P et al (2019) Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 30:1541\u20131557","journal-title":"Ann Oncol"},{"key":"2441_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/bjs5.50157","volume":"3","author":"CW Mok","year":"2019","unstructured":"Mok CW, Tan SM, Zheng Q, Shi L (2019) Network meta-analysis of novel and conventional sentinel lymph node biopsy techniques in breast cancer. BJS Open 3:445\u2013452","journal-title":"BJS Open"},{"key":"2441_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.breast.2022.12.010","volume":"67","author":"V Galimberti","year":"2023","unstructured":"Galimberti V, Fontana SKR, Vicini E, Morigi C, Sargenti M, Corso G, Magnoni F, Intra M (2023) Paolo Veronesi \u201cThis house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients.\u201d The Breast 67:21\u201325","journal-title":"The Breast"},{"key":"2441_CR24","doi-asserted-by":"publisher","unstructured":"Tinterri C, Barbieri E, Sagona A, Di Maria Grimaldi S, Gentile D (2024) De-escalation of axillary surgery in clinically node-positive breast cancer patients treated with neoadjuvant therapy: comparative long-term outcomes of sentinel lymph node biopsy versus axillary lymph node dissection. Cancers (Basel).16(18):3168.\u00a0https:\/\/doi.org\/10.3390\/cancers16183168","DOI":"10.3390\/cancers16183168"},{"issue":"3","key":"2441_CR25","doi-asserted-by":"publisher","first-page":"107967","DOI":"10.1016\/j.ejso.2024.107967","volume":"50","author":"FP Cavalcante","year":"2024","unstructured":"Cavalcante FP, Zerwes FP, Souza ABA, Ziegelmann PK, Alcantara R, Cardoso A, Mattar A, Millen EC, Frasson AL (2024) Use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer. Eur J Surg Oncol. 50(3):107967. https:\/\/doi.org\/10.1016\/j.ejso.2024.107967","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"2441_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamasurg.2024.5913","volume":"160","author":"N Cab\u0131o\u011flu","year":"2025","unstructured":"Cab\u0131o\u011flu N, Ko\u00e7er HB, Karanl\u0131k H et al (2025) Nodal escalation reduction in clinically positive breast cancer surgery. JAMA Surg 160(3):257\u2013266. https:\/\/doi.org\/10.1001\/jamasurg.2024.5913","journal-title":"JAMA Surg"},{"key":"2441_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","volume":"269","author":"JM Simons","year":"2019","unstructured":"Simons JM, Van Nijnatten TJA, Van Der Pol CC, Luiten EJT, Koppert LB, Smidt ML (2019) Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg 269:432\u2013442. https:\/\/doi.org\/10.1097\/SLA.0000000000003075","journal-title":"Ann Surg"},{"key":"2441_CR28","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, Desnyder SM, Hwang RF et al (2016) Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34:1072\u20131078. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094","journal-title":"J Clin Oncol"},{"key":"2441_CR29","doi-asserted-by":"publisher","first-page":"E553","DOI":"10.1097\/SLA.0000000000004572","volume":"276","author":"S Kuemmel","year":"2022","unstructured":"Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, Lubitz J, Hellerhoff K, Ankel C, Gra\u00dfhoff ST et al (2022) A Prospective, Multicenter registry study to evaluate the clinical feasibility of Targeted Axillary Dissection (TAD) in node-positive breast cancer patients. Ann Surg 276:E553\u2013E562. https:\/\/doi.org\/10.1097\/SLA.0000000000004572","journal-title":"Ann Surg"},{"key":"2441_CR30","doi-asserted-by":"publisher","first-page":"100496","DOI":"10.1016\/j.conctc.2019.100496","volume":"17","author":"Corrado Tinterri","year":"2019","unstructured":"Tinterri Corrado, Canavese Giuseppe, Bruzzi Paolo, Dozin Beatrice (2019) Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy. Contempor Clin Trials Commun 17:100496","journal-title":"Contempor Clin Trials Commun"},{"key":"2441_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01052","author":"Giacomo Montagna","year":"2025","unstructured":"Montagna Giacomo, Laws Alison, Ferrucci Massimo, Mrdutt Mary M, Sun Susie X, Bademler Suleyman, Balbaloglu Hakan, Balint-Lahat Nora, Banys-Paluchowski Maggie, Barrio Andrea V, Benson John, Bese Nuran, Boughey Judy, Boyle Marissa, Diego Emilia J, Eller Ruth, Eden Claire, Goldschmidt Maite, Hlavin Callie, Heidinger Martin, Jelinska Justyna, Cakmak G\u00fcldeniz Karadeniz, Kesmodel Susan, Kuerer Henry M, Loesch Julie, Milardi Francesco, Murawa Dawid, Moo Tracy Ann, Menes Tehillah S, Passeri Daniele, Pastoriza Jessica M, Perhavec Andraz, Pislar Nina, Polidorio Nat\u00e1lia, Rami Avina, Ryu Jai Min, Schulz Alexandra, Varadan Sevilimedu M, Ugurlu Umit, Uras Cihan, van Hemert Annemiek, Wong Stephanie M, Yoo Tae-Kyung Robyn, Zhang Jennifer Q, King Tari, Karanlik Hasan, Cabio\u011flu Neslihan, Peeters Marie- Jeanne Vrancken, Morrow Monica, Weber Walter P (2025) Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.24.01052","journal-title":"J Clin Oncol"},{"key":"2441_CR32","unstructured":"(https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01901094)"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02441-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-025-02441-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02441-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:58:44Z","timestamp":1761753524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-025-02441-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":32,"alternative-id":["2441"],"URL":"https:\/\/doi.org\/10.1007\/s13304-025-02441-5","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}